Cochlear Ltd (ASX:COH) is a Sydney-based medical device company that develops and sells implantable hearing solutions. Its products include cochlear implants, bone conduction systems, sound processors and related services for people with moderate to profound hearing loss. Developed markets such as the United States and Western Europe are key regions for the business.

On 2 October 2026, Cochlear shares were trading at $130.32, down 0.02% and broadly unchanged for the session. The company's full-year results, released in August, reported lower profit and provided guidance for FY27, while the company was also affected by changes in the September index rebalance.

Recent Developments

On 18 August 2026, Cochlear released its financial results for the year ended 30 June 2026. The company said the result was at the upper end of revised guidance provided in April. Key figures include:

  • Sales Revenue was $2,343.4 million, down 1% on a reported basis but up 2% in constant currency, with second-half growth of 6%.
  • Underlying net profit was $322.4 million, down 22%, reflecting flat cochlear implant revenue, lower gross margin, transitional costs and currency movements.
  • Statutory net profit was $147.3 million, down 62%, after significant items including fair value, Impairment and cloud expenses.
  • Gross Margin was 71%, compared with 74%.
  • Underlying Earnings Per Share were $4.93, and dividends per share were $3.45, down 20%.

Cochlear implant units increased 5% to 56,692, while implant revenue was flat in constant currency at $1.4 billion, as a higher mix of lower-priced emerging market units affected average pricing. Services revenue rose 6% in constant currency to $634.9 million, and Acoustics revenue rose 1% to $273.3 million.

The company launched the Cochlear Nucleus Nexa System, which it described as the world's first smart cochlear implant system with upgradeable firmware. By June, Nexa accounted for more than 95% of implant sales in developed markets, and an average price increase of 3% was achieved. In the US, revenue increased 4%, with direct-to-consumer surgeries up 10%, although market growth was softer due to insurance approval delays and economic pressures on healthcare. Western Europe revenue declined 8%.

For FY27, Cochlear expects low single-digit constant currency sales revenue growth and underlying net profit of $330 million to $350 million, assuming gradual improvement in developed market implant performance, cost discipline and targeted investment. Separately, on 4 September 2026, S&P Dow Jones Indices announced that Cochlear would be removed from the S&P/ASX 50 Index, effective before the open on 21 September 2026.

Operating expenses rose 5% to $1,251.4 million, and the underlying net profit margin was 14%, compared with 18% in FY25. Cochlear said it is reducing fixed costs to provide flexibility to invest in growth and improve margins, and it is working to accelerate the medicalisation of hearing loss, aiming to make diagnosis, referral and treatment more consistent. The company also said software updates to improve clinician workflows for Nexa are to be deployed over the coming months.

Sector Context

Hearing loss is a growing health issue as populations age, and implantable solutions remain underused relative to the number of people who could benefit. Increasing awareness, diagnosis and referral rates is a long-term focus for the industry, alongside efforts to make adult cochlear implantation a standard of care for severe to profound hearing loss.

Medical device companies face pricing pressure from healthcare systems and insurers, and access to surgery can be influenced by insurance approval processes and hospital capacity. Emerging markets offer Volume growth but often at lower price points. Innovation in implant technology, sound processors and connected services is a key area of competition.

In the US, the largest hearing implant market, surgery volumes are shaped by referral pathways from audiologists and ear, nose and throat specialists, as well as by insurance coverage and approval times. Companies that can influence these pathways through direct-to-consumer outreach and structured referral programs may see more consistent growth. In Europe, healthcare budgets and hospital capacity can affect the pace of implantation.

Risks and Uncertainties

Cochlear's FY26 profit declined, and FY27 guidance assumes a gradual improvement in developed market implant performance, which may not materialise as expected. Insurance approval delays and economic pressures on healthcare in the US could continue to affect surgery volumes, and Western Europe has been weak.

The growing proportion of lower-priced emerging market units weighs on average revenue and margins. Currency movements significantly affect reported results given the company's global footprint. Removal from the S&P/ASX 50 Index may change the composition of its Shareholder base. Competition from other implant manufacturers and the costs of investing in Research and Development are additional considerations.

The statutory result included significant items, such as Fair Value changes and impairment losses on investments, and similar items could affect future reported profit.

The Dividend was reduced by 20% in line with lower earnings, and future dividends will depend on profit recovery. Insurance approval delays in the US are outside the company's direct control.

Catalysts Investors Can Watch

Investors may watch for updates at the company's Annual General Meeting and the half-year result in early 2027 to assess progress against FY27 guidance of $330 million to $350 million in underlying net profit. Developments in US surgery volumes, recovery in Western Europe, the rollout of Nexa software updates and progress on cost reductions will also be relevant.

Updates on gross margin trends and Fixed Cost reductions may also help indicate whether profitability is improving in line with the company's plans.

Progress in emerging markets, where unit growth has been faster, may also be followed.

Wrapping Up

Cochlear's FY26 result showed modest constant currency revenue growth but lower profit, alongside the launch of its Nexa implant system. The company's FY27 outlook depends on improving conditions in developed markets, making implant volumes in the US and Europe key areas to follow.

The Nexa platform's adoption in developed markets provides a reference point for future product upgrades.